Department of Ophthalmology, University of Jordan, Amman, Jordan.
Faculty of Medicine, University of Jordan, Amman, Jordan.
Cutan Ocul Toxicol. 2022 Jun;41(2):113-122. doi: 10.1080/15569527.2022.2050747. Epub 2022 Mar 16.
To examine the effects of systemic isotretinoin treatment on the eye using several ocular examination parameters.
We conducted a systemic review for literature published up to June 2021 in both PubMed and Web of Science databases. We included prospective observational or interventional studies evaluating ocular manifestations of isotretinoin in acne patients. The primary outcome measures were anaesthetized and non-anaesthetized Schirmer test, tear break-up time (TBUT), central corneal thickness (CCT), average retinal nerve fibre layer (RNFL) thickness, ganglion cell-inner plexiform layer (GC-IP) thickness, subfoveal choroidal thickness, axial length, ocular surface disease index (OSDI), meibomian gland expression (MGE) and conjunctival stain. The National Institute of Health (NIH) quality assessment tools were used to assess the data quality. The effect size used to analyse the included studies was the weighted mean difference (WMD) and its related confidence intervals (95%CIs).
Twenty-one publications involving 1105 eyes of 842 participants met the inclusion criteria. Isotretinoin use was significantly associated with reduction in the scores of anaesthetized Schirmer (WMD = -2.23, 95%CI: -3.28 to -1.18), non-anaesthetized Schirmer (WMD = -3.74, 95%CI: -4.23 to -3.25), TBUT (WMD = -3.47, 95%CI: -5.09 to -1.86), and CCT (WMD= -7.39, 95%CI: -13.91 to -0.88). Isotretinoin use was significantly associated with increase of OSDI (WMD = 18.29, 95%CI: 7.54-29.03), MGE (WMD = 1.02, 95%CI: 0.70-1.33) and conjunctival stain scores (WMD = 0.61, 95%CI: 0.47-0.76). No significant change was noted in RNFL thickness (WMD = -0.64, 95%CI: -1.80 to 0.51); GC-IP thickness (WMD = 0.42, 95%CI: -1.08 to 1.92); subfoveal choroidal thickness (WMD = -1.80, 95%CI: -6.69 to 3.09), and axial length (WMD = 0.08, 95%CI: -0.19 to 0.35). A significant heterogeneity was found between the study estimates in each of anaesthetized Schirmer, TBUT, MGE, OSDI, and conjunctival stain tests.
Isotretinoin use results in a statistically significant reduction of the central corneal thickness, TBUT, and Schirmer test scores. A statistically significant increase in MGE, OSDI and conjunctival stain scores was found. No statistically significant change of average RNFL, GC-IP thickness, subfoveal choroidal thickness, or axial length was observed. Further well-designed studies should evaluate the long-term effect of isotretinoin on the eye and reach a firmer conclusion.
使用多种眼部检查参数研究全身性异维 A 酸治疗对眼睛的影响。
我们对截至 2021 年 6 月在 PubMed 和 Web of Science 数据库中发表的文献进行了系统性回顾。我们纳入了评估痤疮患者异维 A 酸眼部表现的前瞻性观察性或干预性研究。主要结局指标为麻醉和非麻醉性 Schirmer 试验、泪膜破裂时间(TBUT)、中央角膜厚度(CCT)、平均视网膜神经纤维层(RNFL)厚度、节细胞内丛状层(GC-IP)厚度、中心凹下脉络膜厚度、眼轴、眼表面疾病指数(OSDI)、睑板腺表达(MGE)和结膜染色。使用美国国立卫生研究院(NIH)质量评估工具评估数据质量。用于分析纳入研究的效应量是加权均数差(WMD)及其相关置信区间(95%CI)。
21 项研究共纳入 842 名参与者的 1105 只眼符合纳入标准。异维 A 酸的使用与麻醉性 Schirmer 评分降低显著相关(WMD=-2.23,95%CI:-3.28 至-1.18)、非麻醉性 Schirmer 评分降低(WMD=-3.74,95%CI:-4.23 至-3.25)、TBUT 降低(WMD=-3.47,95%CI:-5.09 至-1.86)和 CCT 降低(WMD=-7.39,95%CI:-13.91 至-0.88)。异维 A 酸的使用与 OSDI 评分升高显著相关(WMD=18.29,95%CI:7.54-29.03)、MGE 评分升高(WMD=1.02,95%CI:0.70-1.33)和结膜染色评分升高(WMD=0.61,95%CI:0.47-0.76)。RNFL 厚度无显著变化(WMD=-0.64,95%CI:-1.80 至 0.51)、GC-IP 厚度无显著变化(WMD=0.42,95%CI:-1.08 至 1.92)、中心凹下脉络膜厚度无显著变化(WMD=-1.80,95%CI:-6.69 至 3.09)和眼轴长度无显著变化(WMD=0.08,95%CI:-0.19 至 0.35)。在麻醉性 Schirmer、TBUT、MGE、OSDI 和结膜染色试验中,研究估计之间存在显著的异质性。
异维 A 酸的使用导致中央角膜厚度、TBUT 和 Schirmer 试验评分显著降低。MGE、OSDI 和结膜染色评分显著升高。平均 RNFL、GC-IP 厚度、中心凹下脉络膜厚度或眼轴长度无显著变化。需要进一步设计良好的研究来评估异维 A 酸对眼睛的长期影响,并得出更坚定的结论。